Biological Industries Announces Poster Presentation at International Society for Cell Therapy Annual Meeting in Singapore

Dr. Mira Genser-Nir to Present Poster at ISCT 2016 on Novel Set of Serum-Free, Xeno-Free Differentiation Media

KIBBUTZ BEIT HAEMEK, Israel & CROMWELL, Conn.--()--Biological Industries (“BI”; www.bioind.com), a leading developer and manufacturer of cell culture media, molecular biology tools, human cytogenetics media, and custom media manufacturing services, is participating and making a poster presentation at ISCT 2016, the annual meeting of the International Society for Cellular Therapy, 25-28 May, in Singapore.

“A Novel Set of Serum-Free, Xeno-Free Differentiation Media for Adipogenesis, Osteogenesis and Chondrogenesis of Human Mesenchymal Stem Cells from Various Tissue Sources”

The poster presentation, “A Novel Set of Serum-Free, Xeno-Free Differentiation Media for Adipogenesis, Osteogenesis and Chondrogenesis of Human Mesenchymal Stem Cells from Various Tissue Sources,” will be presented by BI’s R&D Product Manager, Mira Genser-Nir, Ph.D.

Presentation Details

  • Abstract Number: 205
  • Presentation Title: A Novel Set of Serum-Free, Xeno-Free Differentiation Media for Adipogenesis, Osteogenesis and Chondrogenesis of Human Mesenchymal Stem Cells from Various Tissue Sources
  • The poster will be available for the duration of the conference

“Human mesenchymal stem cells (hMSCs) are multipotent adult stem cells that can be isolated from various tissues as well as generated in vitro from hESCs and iPS cells,” observed Dr. Genser-Nir. “In order for hMSCs to become the cells of choice for use in regenerative medicine and drug screening, the culture conditions must be improved and differentiation potential is required. We feel that this paper represents a big step toward addressing these issues.”

BI will also have a booth at the conference, #C07-C09.

More information on ISCT 2016 is available at www.isct2016.com.

About Biological Industries

BIOLOGICAL INDUSTRIES (BI) develops, manufactures, and supplies life science products to universities, government research, healthcare institutions, and the biopharmaceutical industry. For over 30 years, BI has been working alongside some of the world’s leading academic researchers and institutes in the development of cell culture media, stem cell reagents, and molecular biology tools. BI also offers custom media development and manufacturing services through its ISO 13485:2003 certified cGMP facilities. BI currently supplies products to researchers and clinicians in over 40 countries with products currently in clinical trials. BI is leveraging their industry-leading experience in cell culture media and pluripotent stem cell technology to help facilitate breakthroughs in stem cell research worldwide. BI is committed to a Culture of Excellence by providing the highest quality reagents and cost-effective, innovative products and services tailored to a customer’s specific needs.

To receive ongoing BI communications, please join our email list or connect with the company on LinkedIn, Twitter, and Facebook.

Contacts

Media:
Gotham Communications for Biological Industries
Bill Douglass, +1-646-504-0890
bill@gothamcomm.com

Release Summary

Biological Industries Announces Poster Presentation at International Society for Cell Therapy Annual Meeting in Singapore

Biological Industries